Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometry.

Bendfeldt K, Taschler B, Gaetano L, Madoerin P, Kuster P, Mueller-Lenke N, Amann M, Vrenken H, Wottschel V, Barkhof F, Borgwardt S, Klöppel S, Wicklein EM, Kappos L, Edan G, Freedman MS, Montalbán X, Hartung HP, Pohl C, Sandbrink R, Sprenger T, Radue EW, Wuerfel J, Nichols TE.

Brain Imaging Behav. 2019 Oct;13(5):1361-1374. doi: 10.1007/s11682-018-9942-9.

PMID:
30155789
2.

Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b.

Goodin DS, Reder AT, Traboulsee AL, Li DK, Langdon D, Cutter G, Cook S, O'Donnell T, Kremenchutzky M, Oger J, Koelbach R, Pohl C, Wicklein EM; IFNB Multiple Sclerosis Study Group and the 16- and 21-Year LTF Investigators.

Mult Scler. 2019 May;25(6):837-847. doi: 10.1177/1352458518773511. Epub 2018 May 15.

PMID:
29761737
3.

Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials.

Buck D, Andlauer TF, Igl W, Wicklein EM, Mühlau M, Weber F, Köchert K, Pohl C, Arnason B, Comi G, Cook S, Filippi M, Hartung HP, Jeffery D, Kappos L, Barkhof F, Edan G, Freedman MS, Montalbán X, Müller-Myhsok B, Hemmer B; BEYOND and BENEFIT Study Groups.

Mult Scler. 2019 Apr;25(4):565-573. doi: 10.1177/1352458518763089. Epub 2018 Mar 9.

PMID:
29521573
4.

Sodium intake and multiple sclerosis activity and progression in BENEFIT.

Fitzgerald KC, Munger KL, Hartung HP, Freedman MS, Montalbán X, Edan G, Wicklein EM, Radue EW, Kappos L, Pohl C, Ascherio A; BENEFIT Study Group.

Ann Neurol. 2017 Jul;82(1):20-29. doi: 10.1002/ana.24965.

5.

The 11-year long-term follow-up study from the randomized BENEFIT CIS trial.

Kappos L, Edan G, Freedman MS, Montalbán X, Hartung HP, Hemmer B, Fox EJ, Barkhof F, Schippling S, Schulze A, Pleimes D, Pohl C, Sandbrink R, Suarez G, Wicklein EM; BENEFIT Study Group.

Neurology. 2016 Sep 6;87(10):978-87. doi: 10.1212/WNL.0000000000003078. Epub 2016 Aug 10.

6.

CFD for wastewater treatment: an overview.

Samstag RW, Ducoste JJ, Griborio A, Nopens I, Batstone DJ, Wicks JD, Saunders S, Wicklein EA, Kenny G, Laurent J.

Water Sci Technol. 2016;74(3):549-63. doi: 10.2166/wst.2016.249. Review.

PMID:
27508360
7.

Good modelling practice in applying computational fluid dynamics for WWTP modelling.

Wicklein E, Batstone DJ, Ducoste J, Laurent J, Griborio A, Wicks J, Saunders S, Samstag R, Potier O, Nopens I.

Water Sci Technol. 2016;73(5):969-82. doi: 10.2166/wst.2015.565.

PMID:
26942517
8.

Reports of patients and relatives from the CogniCIS study about cognition in clinically isolated syndrome: what are our patients telling us?

Langdon DW, Benedict RH, Wicklein EM, Beckmann K, Fredrikson S.

Eur Neurol. 2013;69(6):346-51. doi: 10.1159/000345698. Epub 2013 Apr 26.

PMID:
23635720
9.

Nonsense mutations in SMPX, encoding a protein responsive to physical force, result in X-chromosomal hearing loss.

Huebner AK, Gandia M, Frommolt P, Maak A, Wicklein EM, Thiele H, Altmüller J, Wagner F, Viñuela A, Aguirre LA, Moreno F, Maier H, Rau I, Giesselmann S, Nürnberg G, Gal A, Nürnberg P, Hübner CA, del Castillo I, Kurth I.

Am J Hum Genet. 2011 May 13;88(5):621-7. doi: 10.1016/j.ajhg.2011.04.007. Epub 2011 May 5.

10.

Disability and quality of life in Charcot-Marie-Tooth disease type 1.

Pfeiffer G, Wicklein EM, Ratusinski T, Schmitt L, Kunze K.

J Neurol Neurosurg Psychiatry. 2001 Apr;70(4):548-50.

11.

Clinical and molecular genetic spectrum of autosomal dominant Emery-Dreifuss muscular dystrophy due to mutations of the lamin A/C gene.

Bonne G, Mercuri E, Muchir A, Urtizberea A, Bécane HM, Recan D, Merlini L, Wehnert M, Boor R, Reuner U, Vorgerd M, Wicklein EM, Eymard B, Duboc D, Penisson-Besnier I, Cuisset JM, Ferrer X, Desguerre I, Lacombe D, Bushby K, Pollitt C, Toniolo D, Fardeau M, Schwartz K, Muntoni F.

Ann Neurol. 2000 Aug;48(2):170-80.

PMID:
10939567
12.

Sensitivity and specificity of different conduction block criteria.

Pfeiffer G, Wicklein EM, Wittig K.

Clin Neurophysiol. 2000 Aug;111(8):1388-94.

PMID:
10904219
13.
14.

Prominent sensory ataxia in Guillain-Barré syndrome associated with IgG anti-GD1b antibody.

Wicklein EM, Pfeiffer G, Yuki N, Hartard C, Kunze K.

J Neurol Sci. 1997 Oct 22;151(2):227-9.

PMID:
9349681
15.
16.

[Type I Charcot-Marie-Tooth syndrome. Disability and management].

Wicklein EM, Pfeiffer G, Ratusinski T, Kunze K.

Nervenarzt. 1997 Apr;68(4):358-62. German.

PMID:
9273468
17.

Use of clonazepam and valproate in patients with Lance Adams syndrome.

Wicklein EM, Schwendemann G.

J R Soc Med. 1993 Oct;86(10):618. No abstract available.

Supplemental Content

Loading ...
Support Center